{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:07:27Z","timestamp":1762250847738,"version":"build-2065373602"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,7,23]],"date-time":"2002-07-23T00:00:00Z","timestamp":1027382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their initial therapy. One option for patients with recurrent\/refractory disease is to administer a reinduction regimen that employs a dose\u2010intense combination of anthracycline and cytarabine. These salvage regimens are relatively distinct from the traditional vincristine\/prednisone\u2010based programs that are used typically as primary induction therapy. The authors studied a regimen that contained high\u2010dose cytarabine and a single high dose of idarubicin as salvage induction therapy for patients with recurrent or refractory lymphoblastic disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twenty\u2010nine previously treated adult patients with recurrent or refractory acute lymphoblastic leukemia were treated with a new intensive regimen. Eight patients had primary refractory disease. Twenty\u2010one patients had recurrent disease, and 16 of these patients developed recurrent disease while they were still receiving their primary therapy. The treatment regimen consisted of cytarabine 3.0 g\/m<jats:sup>2<\/jats:sup> by 3\u2010hour infusion daily for 5 days and idarubicin 40 mg\/m<jats:sup>2<\/jats:sup> given as a single dose on Day 3. Filgrastim (granulocyte\u2010colony stimulating factor) 5 \u03bcg\/kg administered subcutaneously every 12 hours was started on Day 7 and was continued until the absolute neutrophil count was &gt; 5000\/\u03bcL. Response was assessed using standard criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>There were 11 complete responses (38%; 95% confidence interval, 20\u201356%). Four patients subsequently underwent allogeneic bone marrow transplantation. Moderate but acceptable toxicity was observed given the severely myelosuppressive nature of the regimen. There was only one treatment\u2010related death (3%). Two patients, both with significant prior exposure to anthracyclines, suffered reductions in left ventricular function to the 20\u201330% range during episodes of severe systemic infection. After recovery from infection, the ejection fraction in one patient improved to 50%.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The authors conclude that this regimen has moderate activity and a relatively low incidence of mortality for this high\u2010risk group of patients. This regimen may be most suitable for patients who can undergo potentially curative allogeneic bone marrow transplantation if they achieve a complete response. Cancer 2002;95:581\u20137. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10707<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10707","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T07:53:08Z","timestamp":1033890788000},"page":"581-587","source":"Crossref","is-referenced-by-count":28,"title":["A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"95","author":[{"given":"Mark A.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Aliff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley R.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt E.","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Maslak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph G.","family":"Jurcic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd E.","family":"Roma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,7,23]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291801"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291810"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.1983.1.8.462","article-title":"Treatment of acute lymphoblastic leukemia in adults: results of the L\u201010 and L\u201010M protocols","volume":"1","author":"Schauer P","year":"1983","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V73.1.57.57","article-title":"Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy","volume":"73","author":"Hussein KK","year":"1989","journal-title":"Blood."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830040209"},{"key":"e_1_2_5_9_2","first-page":"2229","article-title":"A Phase II study with high\u2010dose cytarabine (NS\u2010075) in adult patients with relapsed and refractory acute leukemia","volume":"25","author":"Miyawaki S","year":"1998","journal-title":"Gan To Kagaku Ryoho."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401058"},{"key":"e_1_2_5_11_2","first-page":"664","article-title":"A single high dose of idarubicin combined with high\u2010dose ARA\u2010C (MSKCC ALL\u20103 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University \u201cLa Sapienza\u201d of Rome","volume":"82","author":"Testi AM","year":"1997","journal-title":"Haematologica."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1990.tb00386.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.annonc.a057675","article-title":"Idarubicin and high\u2010dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia","volume":"1","author":"Giona F","year":"1990","journal-title":"Ann Oncol."},{"key":"e_1_2_5_14_2","first-page":"637","article-title":"Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM)","volume":"4","author":"Hiddemann W","year":"1990","journal-title":"Leukemia."},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1200\/JCO.1985.3.7.998","article-title":"Sequential high\u2010dose cytosine arabinoside\u2010asparaginase treatment in advanced childhood leukemia","volume":"3","author":"Wells RJ","year":"1985","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.V72.2.433.bloodjournal722433","article-title":"Amsacrine with high\u2010dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults","volume":"72","author":"Arlin ZA","year":"1988","journal-title":"Blood."},{"volume-title":"Common toxicity criteria","year":"1988","author":"National Cancer Institute, Division of Cancer Treatment","key":"e_1_2_5_17_2"},{"key":"e_1_2_5_18_2","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience","volume":"93","author":"Wetzler M","year":"1999","journal-title":"Blood."},{"key":"e_1_2_5_19_2","first-page":"2404","volume-title":"Cancer principles and practice of oncology","author":"Scheinberg DA","year":"2001"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1270"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2480"},{"key":"e_1_2_5_22_2","first-page":"453","article-title":"Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft\u2010versus\u2010host disease, relapse, and relapse\u2010free survival","volume":"7","author":"Doney K","year":"1991","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(99)00148-4"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V59.2.334.334","article-title":"Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia","volume":"59","author":"Esterhay RJ","year":"1982","journal-title":"Blood."},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1102926.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400861"},{"key":"e_1_2_5_28_2","first-page":"5234","article-title":"Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia","volume":"47","author":"Paciucci PA","year":"1987","journal-title":"Cancer Res."},{"key":"e_1_2_5_29_2","first-page":"425","article-title":"Daunorubicin, vincristine, and prednisone for remission induction in patients with acute lymphoblastic leukemia in relapse","volume":"67","author":"Pavlovsky S","year":"1983","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890701)64:1<16::AID-CNCR2820640104>3.0.CO;2-O"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1318"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00314-0"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10707","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:20:29Z","timestamp":1760296829000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,23]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["10.1002\/cncr.10707"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10707","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2002,7,23]]}}}